Overview

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2024-03-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate MEDI5752 in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
Carboplatin
Pembrolizumab
Pemetrexed